Durect Corporation Extends Deadline for Bausch Health Merger Agreement

Summary

Durect Corporation has extended the deadline for its tender offer in the merger agreement with Bausch Health Americas, Inc. The new deadline is now August 12, 2025, extended from the previous date of August 11, 2025. This amendment follows the initial merger agreement disclosed on July 29, 2025.Reuters

Impact Analysis

The extension of the tender offer deadline allows more time for shareholders to consider the offer and for both companies to finalize the deal details, potentially reflecting ongoing negotiations or additional due diligence. First-order effects include the potential for Durect shareholders to benefit from the acquisition at the agreed price of $1.75 per share, totaling approximately $63 millionReuters. Additionally, once the merger is completed, Durect will delist from NASDAQReuters. For Bausch Health, acquiring Durect strengthens their liver disease treatment pipeline, especially with the addition of Larsucosterol, a promising drug candidate for alcoholic hepatitis, which has shown positive Phase II clinical trial results and received FDA breakthrough therapy designationPharmexec. Second-order effects might include increased competitive pressure on other pharmaceutical companies in the liver disease treatment market. Investment opportunities could arise from this merger, such as investing in Bausch Health to capitalize on its enhanced product portfolio, while risks might involve integration challenges or the possibility of regulatory scrutiny impacting the merger completion.